TMDX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Allegations Against TransMedics - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. - It is alleged that the company engaged in unsafe practices and concealed safety issues, lacking proper safety oversight [3]. - The lawsuit cites a letter from U.S. Representative Paul Gosar accusing TransMedics of misconduct, which led to a decline in stock price following its public disclosure [4]. Group 2: Impact on Stock Price - Following the allegations made by Representative Gosar, TransMedics' stock price fell on February 22, 2024 [4]. - A subsequent report by Scorpion Capital on January 10, 2025, accused TransMedics of overbilling and providing rejected organs, which further contributed to a decline in stock price [5]. Group 3: Class Action Process - Investors who purchased TransMedics securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having recovered $6.6 billion for investors in class action cases [7]. - The firm has been recognized for securing the most monetary relief for investors and has a significant track record in handling large securities class action recoveries [7].